Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study

• Main Authors: Brandon J. Essink (Author), Craig Shapiro (Author), Marie Grace Dawn Isidro (Author), Paul Bradley (Author), Antoinette Pragalos (Author), Mark Bloch (Author), Joel Santiaguel (Author), Melchor Victor Frias (Author), Spiros Miyakis (Author), Margarida Alves de Mesquita (Author), Stefano Berrè (Author), Charlotte Servais (Author), Natasha Waugh (Author), Claudia Hoffmann (Author), Emna Baba (Author), Oliver Schönborn-Kellenberger (Author), Olaf-Oliver Wolz (Author), Sven D. Koch (Author), Tapiwa Ganyani (Author), Philippe Boutet (Author), Philipp Mann (Author), Stefan O. Mueller (Author), Roshan Ramanathan (Author), Martin Robert Gaudinski (Author), Nicolas Vanhoutte (Author)
• Format: Book
• Published: Taylor & Francis Group, 2024-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein. Participants aged ≥ 18 years previously vaccinated with ≥ 2 doses of an mRNA C...